ATE368466T1 - Androgensyntheseinhibitoren - Google Patents

Androgensyntheseinhibitoren

Info

Publication number
ATE368466T1
ATE368466T1 AT98903769T AT98903769T ATE368466T1 AT E368466 T1 ATE368466 T1 AT E368466T1 AT 98903769 T AT98903769 T AT 98903769T AT 98903769 T AT98903769 T AT 98903769T AT E368466 T1 ATE368466 T1 AT E368466T1
Authority
AT
Austria
Prior art keywords
androgen synthesis
synthesis inhibitors
inhibitors
prostate cancer
present
Prior art date
Application number
AT98903769T
Other languages
English (en)
Inventor
Angela Brodie
Yangzhi Ling
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE368466T1 publication Critical patent/ATE368466T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98903769T 1997-02-05 1998-02-05 Androgensyntheseinhibitoren ATE368466T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/795,932 US5994334A (en) 1997-02-05 1997-02-05 Androgen synthesis inhibitors

Publications (1)

Publication Number Publication Date
ATE368466T1 true ATE368466T1 (de) 2007-08-15

Family

ID=25166812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903769T ATE368466T1 (de) 1997-02-05 1998-02-05 Androgensyntheseinhibitoren

Country Status (11)

Country Link
US (2) US5994334A (de)
EP (1) EP1019060B1 (de)
JP (2) JP5043250B2 (de)
AT (1) ATE368466T1 (de)
AU (1) AU6045398A (de)
CA (2) CA2628607C (de)
DE (1) DE69838177T2 (de)
DK (1) DK1019060T3 (de)
ES (1) ES2290984T3 (de)
PT (1) PT1019060E (de)
WO (1) WO1998033506A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2001005364A1 (en) * 1999-07-15 2001-01-25 The Procter & Gamble Company Nitrogen-containing steroid compounds and their use to regulate hair growth
US6093421A (en) * 1999-08-31 2000-07-25 Biotics Research Corporation Maca and antler for augmenting testosterone levels
AU7736300A (en) 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US6413951B2 (en) 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
AU2001268661A1 (en) * 2000-06-27 2002-01-08 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
WO2003059267A2 (en) * 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US20050020550A1 (en) * 2003-04-29 2005-01-27 Morris David J. Selective testicular 11beta-HSD inhibitors and methods of use thereof
EP1781683B1 (de) 2004-08-24 2011-11-16 BTG International Limited Verfahren zur herstellung von 17-vinyl-triflaten als intermediate
CN101141964B (zh) * 2005-01-10 2013-06-05 科尔泰多投资公司 治疗糖尿病、代谢综合症和其它病症的组合物及方法
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
RU2009116632A (ru) * 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
US8435975B2 (en) * 2007-08-24 2013-05-07 Council Of Scientific & Industrial Research Steroidal esters of 17-oximino-5-androsten-3beta-ol
CA2698903A1 (en) * 2007-09-17 2009-03-26 Human Pheromone Sciences, Inc. Fragrance compositions and other compositions which contain naturally occurring substances found in corals
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
US7923426B2 (en) 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
EP2135933B1 (de) 2008-06-20 2013-04-03 The Procter and Gamble Company Waschzusammensetzung
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
EP2393827B1 (de) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Neue prodrugs von steroiden cyp17-inhibitoren/antiandrogenen
EA021840B1 (ru) 2009-09-11 2015-09-30 Бионейчэ Е.А. Лтд. Применение стероидных соединений при воспалительных и аутоиммунных заболеваниях
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
KR101594660B1 (ko) 2010-08-04 2016-02-16 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
EP4717314A2 (de) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituierte 19-nor-pregnanverbindungen, zusammensetzungen und verwendungen davon
KR101352635B1 (ko) * 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
RU2667065C2 (ru) 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
AU2014241816B9 (en) * 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CN107722101A (zh) * 2017-11-03 2018-02-23 郑州大学 甾体吡啶类衍生物及其制备方法和应用
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
CN111333696B (zh) * 2020-04-07 2021-09-24 华中药业股份有限公司 一种治疗痛风的化合物及其制备方法和用途
CN114344310B (zh) * 2021-12-02 2023-10-10 华中药业股份有限公司 一种治疗痛风的药物组合物及其制备方法与用途
US20250312409A1 (en) * 2022-05-10 2025-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2335616A (en) * 1941-11-06 1943-11-30 Parke Davis & Co Steroidal hormone intermediates and their preparation
US2664423A (en) * 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
US2707189A (en) * 1952-09-11 1955-04-26 Upjohn Co 3-keto-17beta-acetamido-4-androstene and process
NL125073C (de) * 1961-07-24
FR1381407A (fr) * 1963-10-17 1964-12-14 Roussel Uclaf Procédé de préparation de composés tétracycliques et produits obtenus par ce procédé
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US3317520A (en) * 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
WO1993023048A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 4-azasteroid 5-alpha-reductase inhibitors
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
WO1997014418A1 (en) * 1995-10-19 1997-04-24 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors

Also Published As

Publication number Publication date
EP1019060B1 (de) 2007-08-01
EP1019060A1 (de) 2000-07-19
CA2279971A1 (en) 1998-08-06
DK1019060T3 (da) 2007-11-12
US6133280A (en) 2000-10-17
JP2001510471A (ja) 2001-07-31
CA2628607A1 (en) 1998-08-06
US5994334A (en) 1999-11-30
CA2279971C (en) 2011-07-12
PT1019060E (pt) 2007-10-03
JP2010024238A (ja) 2010-02-04
EP1019060A4 (de) 2005-04-13
WO1998033506A1 (en) 1998-08-06
CA2628607C (en) 2011-06-07
ES2290984T3 (es) 2008-02-16
DE69838177T2 (de) 2008-04-10
AU6045398A (en) 1998-08-25
DE69838177D1 (de) 2007-09-13
JP5043250B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
DK1019060T3 (da) Androgensynteseinhibitorer
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
CY1107862T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CY1107721T1 (el) Παραγωγα τυροζινης
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
ATE321452T1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
EP1320376A4 (de) Behandlung von prostatakrebs
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
PT880540E (pt) 17-beta-ciclopropil-(amino/oxi)-4-azaesteroides como inibidores activos de 5-alfa-redutase e c17-c20-liase de testosterona
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2001028593A3 (en) Conjugates useful in the treatment of prostate cancer
DE3574563D1 (de) Zusammensetzungen und verbindungen zur behandlung von prostata-adenom.
AU2003236701A8 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1019060

Country of ref document: EP

REN Ceased due to non-payment of the annual fee